Geron Corporation

Geron (GERN) Alert: Johnson Fistel Launches Investigation into Geron Corporation; Investors Encouraged to Contact Firm

SAN DIEGO-PRNewswire—October 29, 2019

Shareholder Rights Law Firm Johnson Fistel, LLP, is investigating potential claims against Geron Corporation (“Geron”) (NASDAQ: GERN) on behalf of investors.  Geron is a biopharmaceutical company.

Specifically, the investigation seeks to determine whether certain statements regarding the results of a clinical drug study of imetelstat called IMbark were false and misleading when made.  Imetelstat was intended to treat certain cancers that occur in bone marrow and the IMbark study was designed to ascertain whether imetelstat helped patients with a cancer called myelofibrosis.  Geron was developing imetelstat in partnership with Janssen Biotech Inc. (“Janssen”), a division of Johnson & Johnson.  On September 27, 2018, the company issued a press release stating that patients in the IMbark study had shown only 10% spleen response rate and 32% symptom response rate.  The company also announced that Janssen had terminated its partnership with the Geron for the development of imetelstat.  Following this news, the price of Geron’s stock dropped from $6.23 to $2.31 on September 27, 2018, a decrease of over 62%.

If you lost money, realized or unrealized on your Geron investment, and are interested in learning more about the investigation or your legal rights and remedies, please contact Jim Baker ([email protected]) by email or phone at 619-814-4471.  If emailing, please include a phone number.

Additionally, you can [click here to join this action]. There is no cost or obligation to you.

About Johnson Fistel, LLP:
Johnson Fistel, LLP is a nationally recognized shareholder rights law firm with offices in California, New York, and Georgia. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits. For more information about the firm and its attorneys, please visit Attorney advertising. Past results do not guarantee future outcomes.

Johnson Fistel, LLP
Jim Baker, 619-814-4471
[email protected]

[click here to join this action]

  • Plaintiff certifies that:
    • 1. Plaintiff did not acquire the security that is the subject of this action at the direction of plaintiff's counsel or in order to participate in this private action or any other litigation under the federal or state securities laws.
    • 2. Plaintiff is willing to serve as a representative party, including providing testimony at deposition and trial, if necessary.
    • 3. Plaintiff represents and warrants that he/she/it is fully authorized to enter into and execute this certification.
    • 4. If a class action is filed, Plaintiff will not accept any payment for serving as a representative party on behalf of a class beyond the Plaintiff's pro rata share of any recovery, except such reasonable costs and expenses (including lost wages) directly relating to the representation of the class as ordered or approved by the court.
    • 5. For purposes of a class action, Plaintiff has made no transaction(s) during the Class Period in the debt or equity securities that are the subject of this action except those set forth below:
  • Acquisitions (include: date shares were acquired, number of shares acquired, and acquisition price per share. Separate each item with a comma. For multiple acquisitions, separate each acquisition with a new line):
  • Sales (include: date shares were sold, number of shares sold, and selling price per share. Separate each item with a comma. For multiple sales, separate each sale with a new line.):
  • During the three years prior to the date of this certification, Plaintiff has not sought to serve or be served as a representative party for a class in an action filed under the federal securities law except if detailed below:

Click to view Retention Agreement